OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

RET-Altered Cancers—A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity
Antoine Desîlets, Matteo Repetto, Soo‐Ryum Yang, et al.
Cancers (2023) Vol. 15, Iss. 16, pp. 4146-4146
Open Access | Times Cited: 15

Showing 15 citing articles:

Tumour-agnostic kinase inhibitors
Jacob J. Adashek, Mina Nikanjam, Razelle Kurzrock
Nature Reviews Drug Discovery (2025)
Closed Access

Pan-Cancer Molecular Biomarkers: Practical Considerations for the Surgical Pathologist
Pari Jafari, Megan Forrest, Jeremy P. Segal, et al.
Modern Pathology (2025), pp. 100752-100752
Closed Access

Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution
Svetlana N. Aleksakhina, A.O. Ivantsov, Evgeny N. Imyanitov
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 4094-4094
Open Access | Times Cited: 2

Current status of precision oncology in adult glioblastoma
Johannes Weller, Anna‐Laura Potthoff, Thomas Zeyen, et al.
Molecular Oncology (2024)
Open Access | Times Cited: 2

Erectile dysfunction in patients treated with selpercatinib for RET altered thyroid cancer
Antonio Matrone, Matthias Kroiß, Matti L. Gild, et al.
Thyroid (2024) Vol. 34, Iss. 9, pp. 1177-1180
Closed Access | Times Cited: 2

Navigating through novelties concerning mCRC treatment—the role of immunotherapy, chemotherapy, and targeted therapy in mCRC
Edward Zheng, Marcin Włodarczyk, Andrzej Węgiel, et al.
Frontiers in Surgery (2024) Vol. 11
Open Access | Times Cited: 1

Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: “Shadows and Fogs”
Gianluca Spitaleri, Pamela Trillo Aliaga, Ilaria Attili, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2877-2877
Open Access | Times Cited: 1

RET is a sex-biased regulator of intestinal tumorigenesis
Sean T. Koester, Naisi Li, Neelendu Dey
Frontiers in Gastroenterology (2024) Vol. 2
Open Access

RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future
Monica F. Chen, Matteo Repetto, Clare Wilhelm, et al.
Drugs (2024) Vol. 84, Iss. 9, pp. 1035-1053
Closed Access

Unveiling the Molecular Features of SCLC With a Clinical RNA Expression Panel
Hilal Özakıncı, Aileen Y. Alontaga, Pedro Cano, et al.
JTO Clinical and Research Reports (2024) Vol. 5, Iss. 11, pp. 100723-100723
Open Access

Advancements and challenges in gastric cancer: epidemiology, biomarkers, and therapeutic strategies
Marina Nishimuni, Laura Carolina López Claro, Maria Ignez Braghiroli
Surgical and Experimental Pathology (2024) Vol. 7, Iss. 1
Open Access

Tissue Biomarkers in Gastric Cancer Treatment: Present and Future
Giulia Airò, Virginia Agnetti, Fabiana Pratticò, et al.
International Journal of Translational Medicine (2024) Vol. 4, Iss. 4, pp. 640-660
Open Access

Page 1

Scroll to top